| Literature DB >> 29182528 |
Shahnaz Haque1, Lorna W Harries2.
Abstract
Splicing events do not always produce a linear transcript. Circular RNAs (circRNAs) are a class of RNA that are emerging as key new members of the gene regulatory milieu, which are produced by back-splicing events within genes. In circRNA formation, rather than being spliced in a linear fashion, exons can be circularised by use of the 3' acceptor splice site of an upstream exon, leading to the formation of a circular RNA species. circRNAs have been demonstrated across species and have the potential to present genetic information in new orientations distinct from their parent transcript. The importance of these RNA players in gene regulation and normal cellular homeostasis is now beginning to be recognised. They have several potential modes of action, from serving as sponges for micro RNAs and RNA binding proteins, to acting as transcriptional regulators. In accordance with an important role in the normal biology of the cell, perturbations of circRNA expression are now being reported in association with disease. Furthermore, the inherent stability of circRNAs conferred by their circular structure and exonuclease resistance, and their expression in blood and other peripheral tissues in association with endosomes and microvesicles, renders them excellent candidates as disease biomarkers. In this review, we explore the state of knowledge on this exciting class of transcripts in regulating gene expression and discuss their emerging role in health and disease.Entities:
Keywords: Circular RNAs; back-splicing; biomarkers; gene regulation; human disease
Year: 2017 PMID: 29182528 PMCID: PMC5748671 DOI: 10.3390/genes8120353
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1The biogenesis of circular RNA (circRNA). The linear primary transcript contains exons (blue boxes), introns (black lines), and possibly repetitive elements or sequence motifs (grey boxes). Circular exons are generated from back-splicing events between the splice donor site of a downstream exon and the splice acceptor site of an upstream exon. This can be mediated by specific sequence elements (grey boxes) or by interaction with RNA binding proteins (RBPs). Splicing events are indicated by dashed lines with double arrowheads. This may result in the production of a circular RNA and a linear RNA which lacks the circularised exons.
Figure 2Proposed roles of circRNA in the regulation of transcription and translation. circRNAs may regulate genes at several levels. (A) Firstly, nuclear circRNAs can interact with promoter regions of target genes and interact with RNA polymerase II (Pol2) to repress or enhance transcription; (B) Secondly, circRNAs can sequester RBPs that regulate mRNA processing and, thus, alter the splicing patterns of the genes in question, or moderate mRNA stability. RBP binding sites are given by dark blue boxes; (C) Thirdly, the biogenesis of circular RNAs may results in the production of a linear RNA lacking the circularised exons. The formation of circRNAs can thus reduce the amount of linear transcript produced; (D) circRNAs can act as micro RNA (miRNA) sponges, sequestering them away from their binding sites in target genes, which are given by dark blue boxes; (E) Circular RNAs can also be translated. The initiation codon is given by a black oval, and the translating ribosome and nascent polypeptide are indicated.
Examples of circRNA and their potential role in disease.
| circRNA | Pathologic Condition | Possible Mode of Function | Potential Application |
|---|---|---|---|
| hsa_circRNA_062557, hsa_circRNA_067130, hsa_circRNA_067209, hsa_circRNA_100914, hsa_circRNA_089761, hsa_circRNA_089763 | moyamoya disease | May sequester miRNAs associated with RNF213 and BRCA1/BRCA2-containing complex subunit 3 | Potential biomarker expressed in blood [ |
| CDR1as | hepatocellular carcinoma | May be a sponge for miR-7 | Biomarker with the ability to predict hepatic microvascular invasion; expressed in hepatocellular carcinoma tissues [ |
| hsa_circ_0001017, hsa_circ_0061276 | gastric cancer | Prognostic, with the ability to predict disease-free survival; expressed in plasma [ | |
| hsa_circ_0089378, hsa_circ_0083357, hsa_circ_0082824, hsa_circ_0068942, hsa_circ_0057576, hsa_circ_0054537, hsa_circ_0051172, hsa_circ_0032970, hsa_circ_0006323 | coronary artery disease | May promote expression of transient receptor potential cation channel subfamily M member 3 by inhibiting hsa-miR-130a-3p | Potential biomarker expressed in plasma [ |
| GSDMB circRNA | multiple sclerosis | Potential biomarker expressed in peripheral blood mononuclear cells [ | |
| hsa_circRNA_105055, hsa_circRNA_086376, hsa_circRNA_102761 | colorectal cancer | May act as sponge for miR-7 regulating target genes | Potential biomarker [ |
| hsa_circ_0092285, hsa_circ_0058794, hsa_circ_0088088, hsa_circ_0038644 | rheumatoid arthritis | May be involved in response to oxidative stress; endocytic traffic in actin cytoskeleton; could promote lipid breakdown and increase free fatty acid levels; could alter lipopolysacccharide (LPS) immune response | Potential biomarker expressed in peripheral blood mononuclear cells [ |
| hsa_circRNA_101308, hsa_circRNA_104423, hsa_circRNA_104916, hsa_circRNA_100269 | gastric cancer | May predict the early recurrence of stage III gastric cancer after radical surgery; expressed in tumour tissues [ | |
| circPVT1 | gastric cancer | May act as sponge for miR-125 family; may promote cell proliferation | Potential prognostic marker with the ability to predict overall survival and disease-free survival; expressed in gastric cancer tissues [ |
| circRNA_104871, circRNA_003524, circRNA_101873, circRNA_103047 | rheumatoid arthritis | Potential biomarker expressed in peripheral blood mononuclear cells [ | |
| hsa_circ_0058246 | gastric cancer | Potential prognostic marker with the ability to predict clinical outcome; expressed in tumour tissues [ | |
| circ-ITCH | hepatocellular carcinoma | May inhibit Wnt/β-Catenin pathway | Potential prognostic marker with the ability to predict survival; expressed in hepatocellular carcinoma tissues [ |
| hsa-circ-0005870 | hypertension | May act as sponge for miRNAs, hsa-miR-6807-3p, hsa-miR-5095, hsa-miR-1273g-3p, hsa-miR-5096, and hsa-miR-619-5p, possibly affecting transforming growth factor beta (TGF-beta) pathway important in hypertension | Potential biomarker expressed in plasma [ |
| hsa_circ_0124644, | coronary artery disease | Potential diagnostic biomarker; expressed in blood [ | |
| circR-284 | carotid disease and ischemic stroke | May act as an inhibitor of miR-221/miR-222 | Potential diagnostic biomarker:expression demonstrated in serum [ |
| circ_0005402, circ_0035560 | multiple sclerosis | Potential biomarker; expressed in leucocytes [ | |
| circZKSCAN1 | hepatocellular carcinoma | May modulate expression of apoptotic genes | Expressed in tumour tissues [ |
| circ_101222 | pre-eclampsia | Potential biomarker; expressed in blood [ | |
| hsa_circ_0054633 | diabetes | Potential biomarker with the ability to predict pre-diabetes and type 2 diabetic status; expressed in blood [ |